{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:25:13Z","timestamp":1793787913925,"version":"4.6.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaci.2026.08.022","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:28:18Z","timestamp":1788589698000},"page":"1178-1191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition"],"prefix":"10.1016","volume":"158","author":[{"given":"Jonathan","family":"Corren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Borish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brightling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Publicover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsna","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Molfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane R.","family":"Parnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-704X","authenticated-orcid":false,"given":"Andrew","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.08.022_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1241","article-title":"TSLP-targeting therapy: beyond allergy?","volume":"13","author":"Ebina-Shibuya","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib2","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI124606","article-title":"Epithelial cell\u2013derived cytokines: more than just signaling the alarm","volume":"129","author":"Roan","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.08.022_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5414\/ALX02296E","article-title":"Epithelial immune regulation of inflammatory airway diseases: chronic rhinosinusitis with nasal polyps (CRSwNP)","volume":"6","author":"Klimek","year":"2022","journal-title":"Allergol Select"},{"key":"10.1016\/j.jaci.2026.08.022_bib4","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1586\/1744666X.2014.967684","article-title":"The importance of TSLP in allergic disease and its role as a potential therapeutic target","volume":"10","author":"Cianferoni","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib5","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41590-019-0524-9","article-title":"TSLP: from allergy to cancer","volume":"20","author":"Corren","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2332\/allergolint.11-RAI-0395","article-title":"TSLP expression: cellular sources, triggers, and regulatory mechanisms","volume":"61","author":"Takai","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2026.08.022_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-020-01513-x","article-title":"CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma","volume":"21","author":"Emson","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2026.08.022_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01193-2022","article-title":"Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma","volume":"61","author":"Gauvreau","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.08.022_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1400696","article-title":"A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti\u2013thymic stromal lymphopoietin antibody, in healthy subjects","volume":"15","author":"Fei","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaci.2026.08.022_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljae266.090","article-title":"717\u2014Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti\u2013thymic stromal lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects","volume":"191","author":"Parish","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.08.022_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaci.2026.03.026","article-title":"AZD8630\/AMG 104, an inhaled anti\u2013thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: phase 1 randomized controlled trial","volume":"158","author":"Doffman","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib15","article-title":"Phase 1 safety and pharmacokinetics study of TAVO101, an anti-human thymic stromal lymphopoietin antibody for the treatment of allergic inflammatory conditions","author":"Han","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2026.08.022_bib16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.70156","article-title":"Verekitug, a novel antibody antagonist to the TSLP receptor in adults with asthma: a 32-week randomized phase 1b multiple ascending-dose trial","volume":"119","author":"Singh","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2026.08.022_bib17","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1038\/s41467-025-63682-x","article-title":"An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial","volume":"16","author":"Xian","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.08.022_bib18","article-title":"Safety, tolerability, and pharmacokinetics of HBM9378 (SKB378\/WIN378), a fully human IgG1 monoclonal antibody against TSLP after single ascending doses in Chinese healthy subjects","volume":"20","author":"Yang","year":"2026","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaci.2026.08.022_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/13543784.2025.2581666","article-title":"Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti\u2013thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study","volume":"34","author":"Zhang","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 69","key":"10.1016\/j.jaci.2026.08.022_bib20","first-page":"OA2332","article-title":"Late breaking abstract\u2014GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma","volume":"66","author":"Singh","year":"2025","journal-title":"Eur Respir J"},{"issue":"Suppl 69","key":"10.1016\/j.jaci.2026.08.022_bib21","first-page":"PA2482","article-title":"A phase 1 randomized, double-blind study of safety, tolerability and pharmacokinetics of Solrikitug in healthy participants","volume":"66","author":"Lalovic","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.08.022_bib22","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib23","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"issue":"Suppl 69","key":"10.1016\/j.jaci.2026.08.022_bib24","first-page":"OA2336","article-title":"Tezepelumab reduces inflammatory biomarker levels in adults with severe chronic rhinosinusitis with nasal polyps overall and in those with comorbid asthma: results from the phase 3 WAYPOINT study","volume":"66","author":"Lipworth","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.08.022_bib25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/alr.70090","article-title":"Early and sustained improvements in sense of smell with tezepelumab treatment in patients with chronic rhinosinusitis with nasal polyps (WAYPOINT)","volume":"16","author":"Mullol","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"issue":"Suppl 1","key":"10.1016\/j.jaci.2026.08.022_bib27","doi-asserted-by":"crossref","first-page":"A7684","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7684","article-title":"Effect of tezepelumab on inflammatory biomarker levels and on exacerbation rates by baseline inflammatory biomarker levels in patients with moderate to very severe chronic obstructive pulmonary disease: results from the COURSE study","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib29","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7684","article-title":"Effect of tezepelumab on lung function in patients with moderate to very severe chronic obstructive pulmonary disease grouped by baseline blood eosinophil count: results from the phase 2a COURSE study","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.08.022_bib32","series-title":"Safety and efficacy of tezepelumab in moderate-to-severe atopic dermatitis: results of a phase 2b randomized, double-blind, placebo-controlled trial","author":"Guttman-Yassky","year":"2022"},{"key":"10.1016\/j.jaci.2026.08.022_bib33","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","article-title":"Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study","volume":"155","author":"McLaren","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib34","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/all.16092","article-title":"Skin, gut, and lung barrier: physiological interface and target of intervention for preventing and treating allergic diseases","volume":"79","author":"Berni Canani","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib37","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2023.11.915","article-title":"Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation","volume":"153","author":"Andreasson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib39","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib40","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.08.022_bib42","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.4049\/jimmunol.1701455","article-title":"Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo: a potential biomarker of severe refractory disease","volume":"200","author":"Li","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1165\/rcmb.2008-0041OC","article-title":"Functional analysis of the thymic stromal lymphopoietin variants in human bronchial epithelial cells","volume":"40","author":"Harada","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2026.08.022_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib45","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.4049\/jimmunol.1000252","article-title":"Thymic stromal lymphopoietin in cigarette smoke\u2013exposed human airway smooth muscle","volume":"185","author":"Smelter","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib46","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01397-2023","article-title":"The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma","volume":"63","author":"Russell","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.08.022_bib47","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood.V86.10.3705.bloodjournal86103705","article-title":"Effects of T-helper 2\u2013type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells","volume":"86","author":"Yanagida","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.022_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1084\/jem.20051745","article-title":"Thymic stromal lymphopoietin: master switch for allergic inflammation","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094369","article-title":"Tezepelumab: a potential new biological therapy for severe refractory asthma","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2026.08.022_bib50","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","article-title":"Mechanisms and pathogenesis of chronic rhinosinusitis","volume":"149","author":"Kato","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib51","doi-asserted-by":"crossref","first-page":"E265","DOI":"10.1002\/lary.26004","article-title":"Prolonged allergen exposure is associated with increased thymic stromal lymphopoietin expression and Th2-skewing in mouse models of chronic rhinosinusitis","volume":"126","author":"Kim","year":"2016","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2026.08.022_bib52","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/1744666X.2023.2235891","article-title":"Olfactory dysfunction in chronic rhinosinusitis: insights into the underlying mechanisms and treatments","volume":"19","author":"Song","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2017.00119","article-title":"Atopic dermatitis studies through in vitro models","volume":"4","author":"De Vuyst","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2026.08.022_bib54","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/ijms21082867","article-title":"Skin barrier abnormalities and immune dysfunction in atopic dermatitis","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2026.08.022_bib55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/all.15603","article-title":"Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances","volume":"78","author":"Kaplan","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110430","article-title":"TSLP\/TSLPR promotes renal fibrosis by activating STAT3 in renal fibroblasts","volume":"121","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2026.08.022_bib57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/bloodadvances.2016002352","article-title":"IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells","volume":"1","author":"Camelo","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2026.08.022_bib58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaci.2017.03.032","article-title":"Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin","volume":"141","author":"Liu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib59","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1097\/MS9.0000000000002107","article-title":"Association between bronchial asthma and TSLP gene polymorphism: a systematic review and meta-analysis","volume":"86","author":"Shrestha","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jaci.2026.08.022_bib60","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ng.888","article-title":"Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations","volume":"43","author":"Torgerson","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2026.08.022_bib61","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaci.2009.04.018","article-title":"A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyperresponsiveness","volume":"124","author":"He","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib62","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5483\/BMBRep.2010.43.7.499","article-title":"Identifying the polymorphisms in the thymic stromal lymphopoietin receptor (TSLPR) and their association with asthma","volume":"43","author":"Yu","year":"2010","journal-title":"BMB Rep"},{"key":"10.1016\/j.jaci.2026.08.022_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.12.085","article-title":"Tezepelumab reduces inflammatory biomarkers as early as week 2 and maintains reductions until week 52 in the phase 3 NAVIGATOR severe asthma trial","volume":"149","author":"Griffiths","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib64","first-page":"A5986","article-title":"Baseline predictors of an enhanced response to tezepelumab treatment versus placebo: results from the phase 3 NAVIGATOR study","volume":"2023","author":"Menzies-Gow","year":"2027","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib65","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s12325-024-02889-8","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma across multiple clinically relevant subgroups in the NAVIGATOR study","volume":"41","author":"Carr","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2026.08.022_bib66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-7961-10-8","article-title":"IL-3 and TNF\u03b1 increase thymic stromal lymphopoietin receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation","volume":"10","author":"Cook","year":"2012","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib68","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib69","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.alit.2025.07.003","article-title":"From mucus plugging to airway dilatation in chronic airway diseases: a perspective on the contribution of the airway microbiome and inflammation","volume":"75","author":"Tanabe","year":"2026","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2026.08.022_bib71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1165\/rcmb.2009-0244OC","article-title":"Interleukin-13\u2013induced mucous metaplasia increases susceptibility of human airway epithelium to rhinovirus infection","volume":"43","author":"Lachowicz-Scroggins","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2026.08.022_bib72","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphys.2012.00460","article-title":"Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment","volume":"3","author":"Brannan","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.jaci.2026.08.022_bib73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib74","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.08.022_bib75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.anai.2024.04.031","article-title":"Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study","volume":"133","author":"Brightling","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib76","first-page":"441","article-title":"Differences and similarities between the upper and lower airway: focusing on innate immunity","volume":"59","author":"Cho","year":"2021","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2026.08.022_bib77","doi-asserted-by":"crossref","first-page":"AB432","DOI":"10.1016\/j.jaci.2025.12.966","article-title":"Efficacy and safety of verekitug (UPB-101) in chronic rhinosinusitis with nasal polyps: results of the phase 2 VIBRANT trial","volume":"157","author":"Han","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib78","article-title":"B32-16 Verekitug, a thymic stromal lymphopoietin receptor antagonist, administered in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma in the Vibrant trial","volume":"212","author":"Sivapalasingam","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/lio2.135","article-title":"Olfactory epithelium: cells, clinical disorders, and insights from an adult stem cell niche","volume":"3","author":"Choi","year":"2018","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.jaci.2026.08.022_bib80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2174\/1570159X17666181206095626","article-title":"Sense of smell: structural, functional, mechanistic advancements and challenges in human olfactory research","volume":"17","author":"Sharma","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jaci.2026.08.022_bib81","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00405-022-07813-w","article-title":"Olfaction in nasal polyp patients after Reboot surgery: an endotype-based prospective study","volume":"280","author":"Gomes","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaci.2026.08.022_bib82","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/alr.22770","article-title":"Olfactory cleft mucus inflammatory proteins in CRS: a case\u2013control study","volume":"11","author":"Smith","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2026.08.022_bib83","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1002\/lary.27112","article-title":"Olfactory and middle meatal cytokine levels correlate with olfactory function in chronic rhinosinusitis","volume":"128","author":"Wu","year":"2018","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2026.08.022_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fncir.2024.1406218","article-title":"Structures and functions of the normal and injured human olfactory epithelium","volume":"18","author":"Kikuta","year":"2024","journal-title":"Front Neural Circuits"},{"key":"10.1016\/j.jaci.2026.08.022_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1371587","article-title":"Apoptosis and turnover disruption of olfactory sensory neurons in eosinophilic chronic rhinosinusitis","volume":"18","author":"Chen","year":"2024","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.jaci.2026.08.022_bib86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2500\/ajra.2010.24.3435","article-title":"Neuropathology of the olfactory mucosa in chronic rhinosinusitis","volume":"24","author":"Yee","year":"2010","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib87","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/alr.23202","article-title":"Olfactory cleft mucus eosinophil-derived neurotoxin better reflects olfactory loss than blood eosinophil counts in patients with chronic rhinosinusitis","volume":"13","author":"Wu","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2026.08.022_bib88","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/coa.12665","article-title":"Outcomes in endoscopic sinus surgery: olfaction, nose scale and quality of life in a prospective cohort study","volume":"41","author":"Andrews","year":"2016","journal-title":"Clin Otolaryngol"},{"issue":"Suppl 1","key":"10.1016\/j.jaci.2026.08.022_bib89","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.anai.2025.08.292","article-title":"Clinical outcomes after tezepelumab cessation following 52 weeks of treatment in adults with severe CRSwNP","volume":"135","author":"Peters","year":"2025","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib90","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000329131","article-title":"Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I\u2013like helicases","volume":"4","author":"Calv\u00e9n","year":"2012","journal-title":"J Innate Immun"},{"key":"10.1016\/j.jaci.2026.08.022_bib91","doi-asserted-by":"crossref","first-page":"L375","DOI":"10.1152\/ajplung.00045.2007","article-title":"Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease","volume":"293","author":"Zhang","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2026.08.022_bib92","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4049\/jimmunol.181.4.2790","article-title":"Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease","volume":"181","author":"Ying","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejim.2024.02.020","article-title":"TSLP is localized in and released from human lung macrophages activated by T2-high and T2-low stimuli: relevance in asthma and COPD","volume":"124","author":"Can\u00e8","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib94","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinbiochem.2014.01.012","article-title":"Increased expression of vascular endothelial growth factor and hypoxia inducible factor-1\u03b1 in lung tissue of patients with chronic bronchitis","volume":"47","author":"Lee","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jaci.2026.08.022_bib97","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1007\/s12325-025-03231-6","article-title":"Effectiveness and safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE study","volume":"42","author":"Lugogo","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2026.08.022_bib98","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9242383","article-title":"Expression of thymic stromal lymphopoietin in immune-related dermatoses","volume":"2022","author":"Li","year":"2022","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaci.2026.08.022_bib99","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1084\/jem.20041503","article-title":"Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin","volume":"202","author":"Yoo","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib101","doi-asserted-by":"crossref","first-page":"11875","DOI":"10.1073\/pnas.0801532105","article-title":"TSLP acts on infiltrating effector T cells to drive allergic skin inflammation","volume":"105","author":"He","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2026.08.022_bib102","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.08.022_bib105","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.08.022_bib106","article-title":"The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis","volume":"10","author":"Napolitano","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2026.08.022_bib107","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.022_bib108","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03007995.2024.2436982","article-title":"Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)","volume":"41","author":"Katoh","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2026.08.022_bib110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00281-021-00857-w","article-title":"What does elevated TARC\/CCL17 expression tell us about eosinophilic disorders?","volume":"43","author":"Catherine","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2026.08.022_bib111","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1046\/j.1523-1747.2000.00115.x","article-title":"A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin","volume":"115","author":"Vestergaard","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.08.022_bib112","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1111\/ijd.12830","article-title":"Serum levels of thymus and activation-regulated chemokine can be used in the clinical evaluation of atopic dermatitis","volume":"54","author":"Gu","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2026.08.022_bib113","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib114","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/cells10010102","article-title":"Thymic stromal lymphopoietin promotes MRGPRX2-triggered degranulation of skin mast cells in a STAT5-dependent manner with further support from JNK","volume":"10","author":"Babina","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2026.08.022_bib115","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib116","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/jid.2014.198","article-title":"TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6","volume":"134","author":"Han","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.08.022_bib117","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1378\/chest.11-1782","article-title":"Mast cell\u2013airway smooth muscle crosstalk: the role of thymic stromal lymphopoietin","volume":"142","author":"Kaur","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2026.08.022_bib118","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.jaip.2020.06.061","article-title":"Leukotriene-associated rash in aspirin-exacerbated respiratory disease","volume":"8","author":"Laidlaw","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.08.022_bib119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell\u2013derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2026.08.022_bib120","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","article-title":"Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels","volume":"14","author":"Maurer","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2026.08.022_bib121","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cea.14256","article-title":"Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study","volume":"53","author":"Corren","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib122","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3390\/ijms25042026","article-title":"The alarmin triad\u2014IL-25, IL-33, and TSLP\u2014serum levels and their clinical implications in chronic spontaneous urticaria","volume":"25","author":"Dobrican-B\u0103ru\u021ba","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2026.08.022_bib123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14309\/ajg.0000000000003194","article-title":"ACG clinical guideline: diagnosis and management of eosinophilic esophagitis","volume":"120","author":"Dellon","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2026.08.022_bib124","article-title":"The dynamic evolution of eosinophilic esophagitis","volume":"15","author":"Farah","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jaci.2026.08.022_bib125","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/all.15233","article-title":"Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: a cross-sectional multi-center study","volume":"77","author":"Greuter","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.022_bib126","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaci.2024.04.006","article-title":"Development and dysfunction of structural cells in eosinophilic esophagitis","volume":"153","author":"Laky","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.022_bib127","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.3390\/ijms21197253","article-title":"Pathogenesis of eosinophilic esophagitis: a comprehensive review of the genetic and molecular aspects","volume":"21","author":"Ryu","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:32:17Z","timestamp":1793784737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926006317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":121,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0091674926006317"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.08.022","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}